Researchers are looking to find interventions for Alzheimer's in Africa, a region that's historically overlooked.
Research in Alzheimer's is progressing rapidly, opening up more interventions and treatments, but there are concerns that not everywhere in the world will benefit from such advances. In fact, most of the dementia cases in the world are in low- and middle-income countries, a number that will only increase as their populations age. The new research will identify the best interventions to try and prevent the progression of Alzheimer's in Africa and allow better brain ageing for all.
The best time to work in Alzheimer's research in my opinion is now and I'm so grateful.
I mean there's been incredible advances in the last decade in terms of more accessible biomarkers
for Alzheimer's. The pathology occurs you know as early as you know 15 years before the onset
of symptoms and we now have biomarkers that are able to detect these brain abnormalities
using a simple blood test. Advances in the field like this offer the opportunity to prevent
Alzheimer's progression but there are concerns that not everyone is getting access to all the
developments that are occurring in the field. There are some low middle income settings
that were missing out on this opportunity for preventing cognitive impairment and dementia.
The World Health Organisation estimates that over 60% of those with dementia live in low and middle
income countries and this will only increase. Population ageing is triggering this rise
in incident dementia but very little is being done in these regions.
To fill this gap, Qi is starting a study called Africa Fingers. It's based on a previous large
randomised trial known as the FINGER study. That study showed that targeting specific factors
like activity levels, diet and cardiovascular health by encouraging people to take part in
exercise and other activities can actually improve cognition. In Africa Fingers Qi wants to find the
best interventions for the region. Here to understand the impact of these interventions
biomarkers alongside cognitive tests will be used to detect and monitor any potential signs
of Alzheimer's. The key objectives I guess are to co-create an intervention protocol
that has a lot of potential for being sustainable and for better adherence for the participants
and then of course we want to test the effectiveness of this multi-modal
intervention, you know adapting the FINGER model to the African context but also addressing
critical factors that we're identifying as being important for the region. To make sure people
really keep up with these interventions Qi believes it's really important to engage with the
community in the study design, to come up with activities that really work in these specific
cultural settings. You know to ensure better adherence we're doing traditional movement
exercises, we're incorporating a lot of traditional music but also ensuring that we're
developing movement strategies that are due to some of the WHO recommendations for instance
for physical activity. To really make interventions that will work to tackle Alzheimer's there also
are specific challenges that need to be considered in the parts of Africa that Qi and the team are
working in. Africa FINGERS is being conducted across four sites in two countries, two of which
are rural, two of which are urban and so you can imagine in rural areas there'll be a lot of
challenges with regards to infrastructure to actually do research. So even things as simple
as blood sample collection right in terms of transportation to attend the research sites
we're working with people who live sometimes less than a dollar a day, really really poor communities
and so we've had to really go back to the drawing board to think about ways by which
we can collect samples because we want to do cutting-edge research here. So we're adopting
novel technologies like you know finger prick blood sample collection. Currently Qi and her
collaborators are still designing the intervention protocol with the local communities but she hopes
that this and other studies like it will pave the way towards equity in Alzheimer's treatment.
I think that everybody deserves to age well and so for me equity refers to providing tools and
developing strategies where people can have successful and sustainable brain aging. By ensuring
that we have biomarkers that are available and accessible to the majority of global populations
I think that we can start to really democratize access to a diagnosis and in that way
of course allowing the potential for prevention. It's such a great time to be in Alzheimer's
research because of the hope it finally gives to patients who you know previously
had very limited hope or things to look forward to.